Table 2 Ongoing immunotherapy/radiotherapy clinical trials
NCT Number | Phase | Regimen | Conditions | Enrollment |
|---|---|---|---|---|
NCT02303366 | I | Stereotactic ablation with anti-PD-1 antibody MK-3475 | Oligometastatic breast cancer | 15 |
T02730130 | II | Pembrolizumab plus radiotherapy | Metastatic breast cancer | 17 |
NCT02499367 | II | Nivolumab after induction | Breast cancer | 84 |
NCT02538471 | II | LY2157299 Monohydrate and radiotherapy | Metastatic breast cancer | 28 |
NCT01862900 | I/II | Stereotactic body radiation with monoclonal antibody to OX40 (MEDI6469) after systemic therapy | Metastatic breast cancer | 40 |
NCT01421017 | I/II | Toll-like Receptor (TLR) 7 agonist, Cyclophosphamide, and radiotherapy | Metastatic breast cancer | 55 |